Literature DB >> 12353294

Navigator-gated free-breathing 3D balanced FFE projection renal MRA: Comparison with contrast-enhanced breath-hold 3D MRA in a swine model.

Elmar Spuentrup1, Arno Buecker, Julius Meyer, Rolf W Günther, Matthias Stuber.   

Abstract

A cardiac-triggered, free-breathing, 3D balanced FFE projection renal MR angiography (MRA) technique with a 2D pencil beam aortic labeling pulse for selective aortic spin tagging was developed. For respiratory motion artifact suppression during free breathing, a prospective real-time navigator was implemented for renal MRA. Images obtained with the new approach were compared with standard contrast-enhanced (CE) 3D breath-hold MRA in seven swine. Signal properties and vessel visualization were analyzed. With the presented technique, high-resolution, high-contrast renal projection MRA with superior vessel length visualization (including a greater visible number of distal branches of the renal arteries) compared to standard breath-hold CE-MRA was obtained. The present results warrant clinical studies in patients with renal artery disease. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353294     DOI: 10.1002/mrm.10271

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  2 in total

1.  Renal arteries: isotropic, high-spatial-resolution, unenhanced MR angiography with three-dimensional radial phase contrast.

Authors:  Christopher J François; Darren P Lum; Kevin M Johnson; Benjamin R Landgraf; Thorsten A Bley; Scott B Reeder; Mark L Schiebler; Thomas M Grist; Oliver Wieben
Journal:  Radiology       Date:  2010-10-27       Impact factor: 11.105

2.  Cylindrical Inversion Pulse for the Reduction of Cardiac Motion Artifacts in Contrast-enhanced Breast MRI.

Authors:  Masami Yoneyama; Masanobu Nakamura; Yuriko Ozawa; Makoto Obara; Tomoyuki Okuaki; Satoshi Tatsuno; Ryuji Sashi; Seishi Sawano; Marc Van Cauteren
Journal:  Magn Reson Med Sci       Date:  2017-05-29       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.